These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25811579)

  • 1. Tamoxifen (selective estrogen-receptor modulators) and aromatase inhibitors as potential perioperative thrombotic risk factors in free flap breast reconstruction.
    Mirzabeigi MN; Nelson JA; Fischer JP; Kovach SJ; Serletti JM; Wu LC; Kanchwala S
    Plast Reconstr Surg; 2015 Apr; 135(4):670e-679e. PubMed ID: 25811579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adjuvant anti-estrogen therapies (tamoxifen and aromatase inhibitors) on perioperative outcomes of breast reconstruction.
    Billon R; Bosc R; Belkacemi Y; Assaf E; SidAhmed-Mezi M; Hersant B; Meningaud JP
    J Plast Reconstr Aesthet Surg; 2017 Nov; 70(11):1495-1504. PubMed ID: 28676319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of perioperative hormonal breast cancer therapy for microvascular flap complications in breast reconstruction.
    Mahrhofer M; Reichert R; Siegwart LC; Russe E; Schoeller T; Wechselberger G; Weitgasser L
    J Plast Reconstr Aesthet Surg; 2023 Oct; 85():143-148. PubMed ID: 37487260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre.
    Samaras S; Ashfield S; Ali SF; Fopp LJ; Benson JR; Malata CM
    J Plast Reconstr Aesthet Surg; 2021 May; 74(5):957-965. PubMed ID: 33221183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is tamoxifen associated with an increased risk for thromboembolic complications in patients undergoing microvascular breast reconstruction?
    Jokuszies A; Radtke C; Betzler C; Branski L; Krämer R; Vogt PM
    Ger Med Sci; 2013; 11():Doc05. PubMed ID: 23423877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Hormone Therapy Use Increase Perioperative Complications in Abdominally Based Microsurgical Breast Reconstruction?
    Tran BNN; Ruan QZ; Cohen JB; Kamali P; Doval AF; Tobias AM; Singhal D; Lin SJ; Lee BT
    Plast Reconstr Surg; 2018 Jun; 141(6):805e-813e. PubMed ID: 29794694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effects of Perioperative Tamoxifen Therapy on Microvascular Flap Complications in Transverse Rectus Abdominis Myocutaneous/Deep Inferior Epigastric Perforator Flap Breast Reconstruction.
    Salibian AA; Bokarius AV; Gu J; Lee Y; Wirth GA; Paydar KZ; Kobayashi MR; Evans GR
    Ann Plast Surg; 2016 Dec; 77(6):630-634. PubMed ID: 26808759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications and thromboembolic events associated with tamoxifen therapy in patients with breast cancer undergoing microvascular breast reconstruction: a systematic review and meta-analysis.
    Parikh RP; Odom EB; Yu L; Colditz GA; Myckatyn TM
    Breast Cancer Res Treat; 2017 May; 163(1):1-10. PubMed ID: 28185144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis.
    Webster TK; Roth SC; Yu D; Baltodano PA; Araya S; Elmer NA; Kaplunov BS; Massada KE; Talemal L; Hackley M; Patel SA
    Breast Cancer Res Treat; 2022 Jun; 193(2):241-251. PubMed ID: 35286525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative Use of Antiestrogen Therapies in Breast Reconstruction: A Systematic Review and Treatment Recommendations.
    Spera LJ; Cook JA; Dolejs S; Fisher C; Lester ME; Hassanein AH
    Ann Plast Surg; 2020 Oct; 85(4):448-455. PubMed ID: 32332390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM; Renshaw L; Williams L; Young O; Murray J; Macaskill EJ; McHugh M; Hannon R; Dixon JM
    Breast Cancer Res Treat; 2010 Feb; 119(3):643-51. PubMed ID: 19941160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    Mortimer JE; Urban JH
    Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective oestrogen receptor modulators, aromatase inhibitors and the female breast.
    Howell A
    Curr Opin Obstet Gynecol; 2005 Aug; 17(4):429-34. PubMed ID: 15976552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
    JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen increases the risk of microvascular flap complications in patients undergoing microvascular breast reconstruction.
    Kelley BP; Valero V; Yi M; Kronowitz SJ
    Plast Reconstr Surg; 2012 Feb; 129(2):305-314. PubMed ID: 21987043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.